Skip to content
Industry
This is research, not advice. We’re not SEBI-registered.

SBC Medical Group Holdings share price today

SBC Medical Group Holdings Incorporated · SBC · Industrials · Consulting Services · price as of the 4 November 2026 close, updated every trading day · results updated weekly · All US stock lists

SBC Medical Group Holdings share price: $5.32 at the close on 4 November 2026, +68.9% in a year.

Turning aroundBusiness trend from fewer quarters than usual
$5.32Price +68.9% in a year
11.1×P/E higher than 79% of the last 1 year
$49.2 MRevenue (Jun 2026) +13.4% on a year ago
$10.7 MProfit (Jun 2026) +335.0% on a year ago
38.5%Operating margin +4.9 points on a year ago
19%ROE FY25
29.0%ROIC against a 6.7% cost of capital: +22.3 points

SBC Medical Group Holdings Incorporated's share price has risen faster than its earnings: +68.9% in a year, against +2.5% for earnings per share.

The main question: the share price moved +68.9% in a year while yearly earnings per share moved +2.5%. The difference came from the market paying a higher multiple.

The price has been between phases, and the P/E is higher than 79% of its own last 1 year. Over the last four quarters, results have been improving, with profit +335.0% on a year earlier, and 70% of the last 3 years' profit came in as cash. What will decide it: whether earnings grow into a price that has already moved.

What is the SBC Medical Group Holdings share price today?

SBC Medical Group Holdings Incorporated's share price was $5.32 at the close on 4 November 2026. That is 35.7% above its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $5, and at that close it sat 96% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). The phase helps read everything below.

Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 13 weeks in a row.

Nov 2026: $5.32, 35.7% above its 200-day average.

  • Price $5.32
  • 50-day avg $4.94
  • 200-day avg $3.92
Nov 2026: $5.32, 35.7% above its 200-day average.
WeekPrice50-day avg200-day avg
11 Jul 2025$5.05––
18 Jul 2025$5.65––
25 Jul 2025$4.76––
1 Aug 2025$4.18––
8 Aug 2025$4.40––
15 Aug 2025$4.46––
22 Aug 2025$4.29––
29 Aug 2025$4.08––
5 Sep 2025$4.15––
12 Sep 2025$4.48––
19 Sep 2025$4.35$4.50–
26 Sep 2025$4.27$4.41–
3 Oct 2025$4.23$4.33–
10 Oct 2025$4.15$4.30–
17 Oct 2025$4.20$4.29–
24 Oct 2025$3.65$4.24–
31 Oct 2025$3.26$4.17–
7 Nov 2025$3.15$4.07–
14 Nov 2025$3.31$4.00–
21 Nov 2025$3.31$3.85–
28 Nov 2025$3.57$3.77–
5 Dec 2025$3.75$3.70–
12 Dec 2025$4.18$3.67–
19 Dec 2025$4.52$3.68–
26 Dec 2025$4.44$3.69–
2 Jan 2026$4.33$3.72–
9 Jan 2026$4.44$3.79–
16 Jan 2026$4.34$3.90–
23 Jan 2026$4.37$4.00–
30 Jan 2026$4.58$4.09–
6 Feb 2026$4.54$4.23–
13 Feb 2026$4.66$4.35–
20 Feb 2026$4.17$4.40–
27 Feb 2026$3.86$4.39–
6 Mar 2026$3.72$4.34–
13 Mar 2026$3.56$4.26–
20 Mar 2026$3.70$4.18–
27 Mar 2026$3.96$4.12–
2 Apr 2026$4.47$4.12–
10 Apr 2026$4.15$4.12–
17 Apr 2026$4.49$4.10–
24 Apr 2026$3.35$3.99$4.14
1 May 2026$3.31$3.87$4.10
8 May 2026$3.18$3.79$4.05
15 May 2026$2.97$3.72$4.01
22 May 2026$3.07$3.65$3.98
29 May 2026$3.21$3.62$3.96
5 Jun 2026$3.01$3.55$3.93
12 Jun 2026$2.87$3.44$3.90
18 Jun 2026$3.07$3.33$3.88
26 Jun 2026$3.30$3.21$3.84
2 Jul 2026$3.25$3.14$3.82
10 Jul 2026$2.97$3.10$3.78
17 Jul 2026$3.08$3.08$3.75
24 Jul 2026$3.06$3.06$3.72
31 Jul 2026$3.06$3.07$3.69
7 Aug 2026$3.06$3.07$3.66
14 Aug 2026$3.66$3.08$3.65
21 Aug 2026$4.00$3.15$3.66
28 Aug 2026$4.05$3.27$3.68
4 Sep 2026$4.12$3.38$3.71
11 Sep 2026$4.46$3.48$3.73
18 Sep 2026$4.75$3.64$3.76
25 Sep 2026$4.90$3.82$3.79
2 Oct 2026$5.09$4.02$3.81
9 Oct 2026$5.42$4.24$3.84
16 Oct 2026$5.16$4.46$3.86
23 Oct 2026$5.28$4.70$3.89
30 Oct 2026$5.28$4.87$3.91
4 Nov 2026$5.32$4.94$3.92
Weekly closing price ($) with its 50-day and 200-day averages. 1-year window.

Week by week since 2025: did it beat the S&P 500 over the past 13 weeks?

Ahead in 25 of 57 weeks

Week by week since 2025: did it beat the S&P 500 over the past 13 weeks?
Week13-week return vs S&P 500
11 Jul 2025no S&P 500 reading
18 Jul 2025no S&P 500 reading
25 Jul 2025no S&P 500 reading
1 Aug 2025no S&P 500 reading
8 Aug 2025no S&P 500 reading
15 Aug 2025no S&P 500 reading
22 Aug 2025no S&P 500 reading
29 Aug 2025no S&P 500 reading
5 Sep 2025no S&P 500 reading
12 Sep 2025no S&P 500 reading
19 Sep 2025no S&P 500 reading
26 Sep 2025no S&P 500 reading
3 Oct 2025no S&P 500 reading
10 Oct 2025−22.5%
17 Oct 2025−31.5%
24 Oct 2025−29.6%
31 Oct 2025−31.7%
7 Nov 2025−33.7%
14 Nov 2025−30.2%
21 Nov 2025−25.0%
28 Nov 2025−18.4%
5 Dec 2025−15.6%
12 Dec 2025−10.4%
19 Dec 2025+1.4%
26 Dec 2025−0.3%
2 Jan 2026+0.3%
9 Jan 2026+0.7%
16 Jan 2026−0.8%
23 Jan 2026+18.0%
30 Jan 2026+39.0%
6 Feb 2026+41.2%
13 Feb 2026+39.3%
20 Feb 2026+21.4%
27 Feb 2026+7.7%
6 Mar 2026+1.1%
13 Mar 2026−12.0%
20 Mar 2026−13.4%
27 Mar 2026−2.7%
2 Apr 2026+7.2%
10 Apr 2026−4.4%
17 Apr 2026+0.8%
24 Apr 2026−26.9%
1 May 2026−31.9%
8 May 2026−36.8%
15 May 2026−44.7%
22 May 2026−34.5%
29 May 2026−27.1%
5 Jun 2026−28.8%
12 Jun 2026−31.4%
18 Jun 2026−32.2%
26 Jun 2026−31.6%
2 Jul 2026−40.9%
10 Jul 2026−39.5%
17 Jul 2026−36.1%
24 Jul 2026−12.2%
31 Jul 2026−11.2%
7 Aug 2026−8.6%
14 Aug 2026+18.2%
21 Aug 2026+27.6%
28 Aug 2026+24.5%
4 Sep 2026+32.5%
11 Sep 2026+52.4%
18 Sep 2026+52.7%
25 Sep 2026+42.7%
2 Oct 2026+53.3%
9 Oct 2026+79.4%
16 Oct 2026+64.8%
23 Oct 2026+69.7%
30 Oct 2026+71.4%
4 Nov 2026+74.7%
Each bar is one week, from 2025 to now (57 weeks with a reading). Green means the stock's return over the previous 13 weeks beat the S&P 500; red means it trailed. The colour is strongest at a gap of 25 percentage points or more. A gap means there is no reading for that week.

Over the last 1 year the share price moved +5% while the S&P 500 moved +23%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

What dividend does SBC Medical Group Holdings pay?

SBC Medical Group Holdings Incorporated pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes.

Which stock lists is SBC Medical Group Holdings on?

SBC Medical Group Holdings is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list.

Is SBC Medical Group Holdings profitable?

SBC Medical Group Holdings Incorporated earned $10.7 M of net profit in the Jun 2026 quarter, +335.0% on the same quarter a year earlier. Full-year FY25 profit was $51.0 M. Over 3 years profit has grown 100.6% a year on average. That is 21.7% of the quarter's revenue. The same quarter a year earlier earned $2.5 M.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

For the full year, FY25 profit was $51.0 M (+9.4% on the year before).

FY25 profit $51.0 M (+9.4% on the year before), 100.6% a year over 3 years

  • Net profit $51.0 M
FY25 profit $51.0 M (+9.4% on the year before), 100.6% a year over 3 years
QuarterNet profit
FY22$6.3 M
FY23$39.4 M
FY24$46.6 M
FY25$51.0 M

Growth on a year earlier

  • Growth on a year earlier 9.4%
Growth on a year earlier
QuarterGrowth on a year earlier
FY22–
FY23523.4%
FY2418.4%
FY259.4%
Top: net profit each year, $ M. Below: growth on the year before, %. 4-year window. A grey bar is lower than the year before.

Jun 2026: $10.7 M (+335.0% on a year earlier)

  • Net profit (quarterly) $10.7 M
Jun 2026: $10.7 M (+335.0% on a year earlier)
QuarterNet profit (quarterly)
Sep 2023$8.4 M
Dec 2023$14.3 M
Mar 2024$18.8 M
Jun 2024$18.5 M
Sep 2024$2.8 M
Dec 2024$6.5 M
Mar 2025$21.5 M
Jun 2025$2.5 M
Sep 2025$12.8 M
Dec 2025$14.2 M
Mar 2026$11.3 M
Jun 2026$10.7 M

Growth on a year earlier

  • Growth on a year earlier 335%
Growth on a year earlier
QuarterGrowth on a year earlier
Sep 2023–
Dec 2023–
Mar 2024212.5%
Jun 202473.2%
Sep 2024−66.1%
Dec 2024−54.4%
Mar 202514.6%
Jun 2025−86.7%
Sep 2025352.7%
Dec 2025117.2%
Mar 2026−47.4%
Jun 2026335%
Top: net profit each quarter, $ M. Below: growth on the same quarter a year earlier, %. Last 12 quarters. A grey bar is lower than the quarter before.

Why profit moved: revenue changed +13.4% on a year earlier and the margin moved +4.9 percentage points. Most of the change came from keeping more of each sale.

On average over the last four quarters, profit changed +189.4% and revenue −6.2%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra dollar of revenue adds more to profit.

How much revenue does SBC Medical Group Holdings make, and is it growing?

SBC Medical Group Holdings Incorporated reported $49.2 M of revenue in the Jun 2026 quarter, +13.4% on the same quarter a year earlier. Over 3 years it has grown −0.1% a year on average. The last full year, FY25, came in at $174 M. The last four reported quarters add to $175 M.

Revenue is everything the company billed its customers in the period.

FY25 revenue was $174 M, −15.5% on the year before.

FY25 revenue $174 M (−15.5% on the year before), −0.1% a year over 3 years

  • Revenue $174 M
FY25 revenue $174 M (−15.5% on the year before), −0.1% a year over 3 years
QuarterRevenue
FY22$174 M
FY23$194 M
FY24$205 M
FY25$174 M

Growth on a year earlier

  • Growth on a year earlier −15.5%
Growth on a year earlier
QuarterGrowth on a year earlier
FY22–
FY2311.1%
FY246.1%
FY25−15.5%
Top: revenue each year, $ M. Below: growth on the year before, %. 4-year window. A grey bar is lower than the year before.

Jun 2026: $49.2 M (+13.4% on a year earlier)

  • Revenue (quarterly) $49.2 M
Jun 2026: $49.2 M (+13.4% on a year earlier)
QuarterRevenue (quarterly)
Sep 2023$47.3 M
Dec 2023$62.4 M
Mar 2024$54.8 M
Jun 2024$53.1 M
Sep 2024$53.1 M
Dec 2024$44.4 M
Mar 2025$47.3 M
Jun 2025$43.4 M
Sep 2025$43.4 M
Dec 2025$39.6 M
Mar 2026$43.1 M
Jun 2026$49.2 M

Growth on a year earlier

  • Growth on a year earlier 13.4%
Growth on a year earlier
QuarterGrowth on a year earlier
Sep 2023–
Dec 2023–
Mar 202427.7%
Jun 202429.5%
Sep 202412.3%
Dec 2024−28.8%
Mar 2025−13.6%
Jun 2025−18.3%
Sep 2025−18.3%
Dec 2025−10.9%
Mar 2026−9%
Jun 202613.4%
Top: revenue each quarter, $ M. Below: growth on the same quarter a year earlier, %. Last 12 quarters. A grey bar is lower than the quarter before.

Recent pace: the last four quarters grew −6.2% on average, against −0.1% a year over the longer run, so this year is growing slower than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew −6.9%, against −10.3% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +47.1%, against −9.6% a year (accelerating).

How much of every $100 of sales does SBC Medical Group Holdings keep?

SBC Medical Group Holdings Incorporated's operating margin was 38.5% in the Jun 2026 quarter, 4.9 percentage points higher than the same quarter a year ago. Across 4 years it has been between 11.7% and 41.6%. The latest quarter is within that range.

Operating margin is what is left from every $100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

Why the margin moved: operating margin changed +4.9 percentage points on the year while gross margin changed +3.9 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

FY25: 38.9%, within a range of 11.7% to 41.6% over 4 years

  • Operating margin 38.9%
FY25: 38.9%, within a range of 11.7% to 41.6% over 4 years
QuarterOperating margin
FY2211.7%
FY2336.5%
FY2441.6%
FY2538.9%

Change on the year before (points)

  • Change on the year before (points) −2.7 pts
Change on the year before (points)
QuarterChange on the year before (points)
FY22–
FY23+24.8 pts
FY24+5.1 pts
FY25−2.7 pts
Operating margin each year, % (top). Below: change on the year before, in percentage points. 4-year window.

Jun 2026: operating margin 38.5% (+4.9 points on a year earlier)

  • Operating margin 38.5%
Jun 2026: operating margin 38.5% (+4.9 points on a year earlier)
QuarterOperating margin
Sep 202342.4%
Dec 202338.5%
Mar 202444.6%
Jun 202451.4%
Sep 202426.1%
Dec 202444.5%
Mar 202551.1%
Jun 202533.6%
Sep 202536.6%
Dec 202532.5%
Mar 202641.2%
Jun 202638.5%

Change on a year earlier (points)

  • Change on a year earlier (points) +4.9 pts
Change on a year earlier (points)
QuarterChange on a year earlier (points)
Sep 2023–
Dec 2023–
Mar 2024+18.8 pts
Jun 2024+13.4 pts
Sep 2024−16.3 pts
Dec 2024+6.0 pts
Mar 2025+6.5 pts
Jun 2025−17.8 pts
Sep 2025+10.5 pts
Dec 2025−12.0 pts
Mar 2026−9.9 pts
Jun 2026+4.9 pts
Top: quarterly operating margin, %. Below: change on the same quarter a year earlier, in percentage points. Last 12 quarters. Operating profit as a share of revenue, each quarter.

Is SBC Medical Group Holdings' profit turning into cash?

Over the last 3 years, 70% of SBC Medical Group Holdings Incorporated's reported profit came in as cash from its operations, so most of the profit is real cash. In FY25 it brought in $24.7 M of operating cash against $51.0 M of profit. After $2.4 M of spending on assets, $22.3 M was left over as free cash.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

FY25: operating cash $24.7 M against profit $51.0 M; 70% of 3 years' profit came in as cash

  • Operating cash $24.7 M
  • Net profit $51.0 M
  • Free cash $22.3 M
FY25: operating cash $24.7 M against profit $51.0 M; 70% of 3 years' profit came in as cash
QuarterOperating cashNet profitFree cash
FY22$0$6.3 M–
FY23$50.7 M$39.4 M$41.1 M
FY24$20.6 M$46.6 M$17.2 M
FY25$24.7 M$51.0 M$22.3 M
Operating cash flow and net profit each year, $ M. The line is free cash flow: operating cash minus spending on assets. 4-year window, yearly figures. FY22 was an acquisition year, so its point is cut off at the edge.

Jun 2026: operating cash $22.5 M = 211% of the quarter's profit

  • Operating cash (quarterly) $22.5 M
Jun 2026: operating cash $22.5 M = 211% of the quarter's profit
QuarterOperating cash (quarterly)
Sep 2023$23.2 M
Dec 2023$27.9 M
Mar 2024$3.7 M
Jun 2024$19.2 M
Sep 2024$5.0 M
Dec 2024−$7.3 M
Mar 2025$1.9 M
Jun 2025−$8.3 M
Sep 2025−$20.9 M
Dec 2025$52.0 M
Mar 2026$9.2 M
Jun 2026$22.5 M

Operating cash as % of profit

  • Operating cash as % of profit 211%
Operating cash as % of profit
QuarterOperating cash as % of profit
Sep 2023277%
Dec 2023195%
Mar 202420%
Jun 2024104%
Sep 2024177%
Dec 2024−112%
Mar 20259%
Jun 2025−339%
Sep 2025−163%
Dec 2025366%
Mar 202682%
Jun 2026211%
Top: operating cash each quarter, $ M. Below: operating cash as a % of net profit; 100% means all of the quarter's profit came in as cash. Last 12 quarters.

Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason.

What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building.

Where does SBC Medical Group Holdings' cash go?

SBC Medical Group Holdings Incorporated does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $15.3 M on assets over the last 3 years. Averaged over those years that is 2.9% of FY25 revenue a year.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn.

Spending on assets: $15.3 M over the last 3 years.

FY25: capex $2.4 M, steady spending

  • Capex $2.4 M
FY25: capex $2.4 M, steady spending
QuarterCapex
FY22$24.9 M
FY23$9.5 M
FY24$3.4 M
FY25$2.4 M
Capital spending each year, $ M.

Jun 2026: capex $0.5 M in the quarter

  • Capex (quarterly) $0.5 M
Jun 2026: capex $0.5 M in the quarter
QuarterCapex (quarterly)
Sep 2023$1.3 M
Dec 2023$6.8 M
Mar 2024$0.7 M
Jun 2024$0.9 M
Sep 2024$1.3 M
Dec 2024$0.6 M
Mar 2025$0.8 M
Jun 2025$0.5 M
Sep 2025$0.2 M
Dec 2025$0.9 M
Mar 2026$0.5 M
Jun 2026$0.5 M

Free cash

  • Free cash $22.0 M
Free cash
QuarterFree cash
Sep 2023$21.8 M
Dec 2023$21.1 M
Mar 2024$3.0 M
Jun 2024$18.3 M
Sep 2024$3.8 M
Dec 2024−$7.9 M
Mar 2025$1.2 M
Jun 2025−$8.9 M
Sep 2025−$21.1 M
Dec 2025$51.0 M
Mar 2026$8.7 M
Jun 2026$22.0 M
Top: capital spending each quarter, $ M. Below: free cash flow, $ M. Last 12 quarters.

In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns.

What is SBC Medical Group Holdings' P/E ratio, and how does it compare with its own history?

SBC Medical Group Holdings Incorporated's P/E is 11.1×, near the high end of its own history: higher than 79% of past readings. Its usual P/E (the middle reading) is 8.9×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many dollars the market pays for each dollar of yearly profit.

P/E 11.1× against a usual 8.9×: near the high end of its own history: higher than 79% of past readings

  • P/E 11.1×
  • Median 8.87×
P/E 11.1× against a usual 8.9×: near the high end of its own history: higher than 79% of past readings
WeekP/EMedian
11 Jul 202515.5×8.87×
18 Jul 202515.5×8.87×
25 Jul 202514.7×8.87×
1 Aug 202512.9×8.87×
8 Aug 202513.5×8.87×
15 Aug 202513.7×8.87×
22 Aug 202513.2×8.87×
29 Aug 202512.6×8.87×
5 Sep 202512.8×8.87×
12 Sep 202513.8×8.87×
19 Sep 202513.4×8.87×
26 Sep 202513.1×8.87×
3 Oct 202510.1×8.87×
10 Oct 20259.86×8.87×
17 Oct 20259.98×8.87×
24 Oct 20258.67×8.87×
31 Oct 20257.74×8.87×
7 Nov 20257.48×8.87×
14 Nov 20257.86×8.87×
21 Nov 20257.86×8.87×
28 Nov 20258.48×8.87×
5 Dec 20258.91×8.87×
12 Dec 20259.93×8.87×
19 Dec 202510.7×8.87×
26 Dec 202510.6×8.87×
2 Jan 20268.75×8.87×
9 Jan 20268.97×8.87×
16 Jan 20268.77×8.87×
23 Jan 20268.83×8.87×
30 Jan 20269.25×8.87×
6 Feb 20269.17×8.87×
13 Feb 20269.41×8.87×
20 Feb 20268.42×8.87×
27 Feb 20267.80×8.87×
6 Mar 20267.52×8.87×
13 Mar 20267.19×8.87×
20 Mar 20267.47×8.87×
27 Mar 20268.00×8.87×
2 Apr 202611.3×8.87×
10 Apr 202610.4×8.87×
17 Apr 202611.3×8.87×
24 Apr 20268.44×8.87×
1 May 20268.34×8.87×
8 May 20268.01×8.87×
15 May 20267.48×8.87×
22 May 20267.73×8.87×
29 May 20268.09×8.87×
5 Jun 20267.58×8.87×
12 Jun 20267.23×8.87×
18 Jun 20267.73×8.87×
26 Jun 20268.31×8.87×
2 Jul 20266.80×8.87×
10 Jul 20266.21×8.87×
17 Jul 20266.44×8.87×
24 Jul 20266.40×8.87×
31 Jul 20266.40×8.87×
7 Aug 20266.40×8.87×
14 Aug 20267.66×8.87×
21 Aug 20268.37×8.87×
28 Aug 20268.47×8.87×
4 Sep 20268.62×8.87×
11 Sep 20269.33×8.87×
18 Sep 20269.94×8.87×
25 Sep 202610.3×8.87×
2 Oct 202610.7×8.87×
9 Oct 202611.3×8.87×
16 Oct 202610.8×8.87×
23 Oct 202611.1×8.87×
30 Oct 202611.1×8.87×
4 Nov 202611.1×8.87×

Earnings per share, 12 months

  • Earnings per share, 12 months $0.48
Earnings per share, 12 months
WeekEarnings per share, 12 months
11 Jul 2025–
18 Jul 2025–
25 Jul 2025–
1 Aug 2025–
8 Aug 2025–
15 Aug 2025–
22 Aug 2025–
29 Aug 2025–
5 Sep 2025–
12 Sep 2025–
19 Sep 2025–
26 Sep 2025$0.33
3 Oct 2025$0.33
10 Oct 2025$0.33
17 Oct 2025$0.33
24 Oct 2025$0.33
31 Oct 2025$0.33
7 Nov 2025$0.33
14 Nov 2025$0.33
21 Nov 2025$0.33
28 Nov 2025$0.33
5 Dec 2025$0.33
12 Dec 2025$0.33
19 Dec 2025$0.33
26 Dec 2025$0.42
2 Jan 2026$0.42
9 Jan 2026$0.42
16 Jan 2026$0.42
23 Jan 2026$0.42
30 Jan 2026$0.42
6 Feb 2026$0.42
13 Feb 2026$0.42
20 Feb 2026$0.42
27 Feb 2026$0.42
6 Mar 2026$0.42
13 Mar 2026$0.42
20 Mar 2026$0.42
27 Mar 2026$0.49
2 Apr 2026$0.49
10 Apr 2026$0.49
17 Apr 2026$0.49
24 Apr 2026$0.49
1 May 2026$0.49
8 May 2026$0.49
15 May 2026$0.49
22 May 2026$0.49
29 May 2026$0.49
5 Jun 2026$0.49
12 Jun 2026$0.49
18 Jun 2026$0.49
26 Jun 2026$0.40
2 Jul 2026$0.40
10 Jul 2026$0.40
17 Jul 2026$0.40
24 Jul 2026$0.40
31 Jul 2026$0.40
7 Aug 2026$0.40
14 Aug 2026$0.40
21 Aug 2026$0.40
28 Aug 2026$0.40
4 Sep 2026$0.40
11 Sep 2026$0.40
18 Sep 2026$0.40
25 Sep 2026$0.48
2 Oct 2026$0.48
9 Oct 2026$0.48
16 Oct 2026$0.48
23 Oct 2026$0.48
30 Oct 2026$0.48
4 Nov 2026$0.48
Top: P/E each week. Below: earnings per share, trailing twelve months, a step line that moves once a quarter; 1 year of history; short peaks above 16× are drawn at the top edge.
11.1×P/E · higher than 79% of its last 1 year
2.14PEG · today, as reported

Why the multiple is where it is: over the past year earnings per share moved +2.5% while the price moved +68.9%. The price did better than earnings, which pushed the multiple up within its own range.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Is the SBC Medical Group Holdings business getting better or worse?

SBC Medical Group Holdings Incorporated's business is turning around. Profit growth has swung from −54.4% at its low to +335.0%, rising from a low 5 quarters ago (from single-quarter figures), with ROCE falling at 22.4%. This is based on 11 quarters of 3 measures, with some gaps.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.

Growth year by year: revenue −15.5% in FY25, profit +9.4%

  • Revenue growth −15.5%
Growth year by year: revenue −15.5% in FY25, profit +9.4%
QuarterRevenue growth
FY22–
FY2311.1%
FY246.1%
FY25−15.5%

Profit growth, EPS growth

  • Profit growth 9.4%
  • EPS growth 2.5%
Profit growth, EPS growth
QuarterProfit growthEPS growth
FY22––
FY23300%−47.4%
FY2418.4%15.5%
FY259.4%2.5%
Growth on the year before, each year, %. Top: revenue. Below: net profit and earnings per share, on their own scale because profit growth swings much more. Zero line drawn. Turnaround-year jumps are drawn at the edge (▲).

Three growth lines over twelve quarters: revenue accelerating, profit accelerating

  • Revenue 13.4%
Three growth lines over twelve quarters: revenue accelerating, profit accelerating
QuarterRevenue
Sep 2023–
Dec 2023–
Mar 202427.7%
Jun 202429.5%
Sep 202412.3%
Dec 2024−28.8%
Mar 2025−13.6%
Jun 2025−18.3%
Sep 2025−18.3%
Dec 2025−10.9%
Mar 2026−9%
Jun 202613.4%

Profit, EPS

  • Profit 300%
  • EPS 46.9%
Profit, EPS
QuarterProfitEPS
Sep 2023––
Dec 2023––
Mar 2024212.5%–
Jun 202473.2%–
Sep 2024−66.1%–
Dec 2024−54.4%–
Mar 202514.6%−72.1%
Jun 2025−86.7%−48.9%
Sep 2025300%−27.2%
Dec 2025117.2%1.3%
Mar 2026−47.4%−20.2%
Jun 2026300%46.9%
Growth on a year earlier, % at each quarter end. Top: revenue. Below: profit and earnings per share, on their own scale because they swing much more. Each is measured over the last 12 months. Where the 12-month history is short, the line uses single-quarter growth instead, which is noisier; extreme jumps from a tiny base are evened out before reading. Extreme jumps from a tiny base are drawn at the edge (▲). A gap means there is no reading for that quarter.

ROCE: the return line, worked out each quarter

  • ROCE 22.4%
ROCE: the return line, worked out each quarter
QuarterROCE
Sep 2023–
Dec 202342.5%
Mar 202457.1%
Jun 202463.9%
Sep 202452.2%
Dec 202446%
Mar 202541.4%
Jun 202533.3%
Sep 202529.7%
Dec 202525.7%
Mar 202621.7%
Jun 202622.4%
Operating profit over the last 12 months (before interest and tax) as a share of average capital employed (total assets minus current liabilities), %.
RecoveringRevenue growth · latest +13.4%, range −28.8% to +29.5%
FlatProfit growth · latest +335.0%, range −86.7% to +100.0%
Turning downROCE · latest 22.4%, range 21.7% to 63.9%

Why it matters: a turn in growth is often where a bigger change starts. The lines say a turn is forming, so the question is whether the next quarters confirm it.

One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result.

This reading has some gaps: at least one line is short, or the return line is not the quarterly series, so treat it with a little more caution.

Compound annual growth rate (%)

Compound annual growth rate over each period, %. Revenue, profit and EPS come from yearly figures; the stock price row is price growth over the same periods. A dash means no figure for that period, or the starting year was a loss.

Compound annual growth rate (%)
Measure1yr3yr5yr10yr
Revenue−15.5%−0.1%——
Profit+9.4%+100.6%——
EPS+2.5%−14.6%——
Stock price+68.9%———
+13.4%Revenue growth (Jun 2026) · latest quarter against a year ago
+335.0%Profit growth (Jun 2026) · latest quarter against a year ago
−0.1%Revenue, 3 years · yearly growth over the long run

How much does SBC Medical Group Holdings earn on its capital?

SBC Medical Group Holdings Incorporated earned a ROE of 19% in FY25. That is up from a low of 6% in FY22. Its return on capital used (ROIC) is 22.3 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 29.4% net margin and 0.46× asset turnover (sales divided by assets).

Return on equity (ROE) is the profit the business earns on its shareholders’ money. We do not have the full capital split, so ROE is the longest history we can draw here.

Why the return is what it is (FY25): a 29.4% net margin × 0.46× asset turnover × 1.44× leverage (assets divided by equity) ≈ 19.5% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed.

The key test, return on capital used minus the cost of capital: 29.0% − 6.7% = +22.3 percentage points. The 6.7% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. A gap this wide means each dollar put back into the business creates more than a dollar of value.

The 29.0% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 36.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method.

FY25: ROE 19%, the climb back from FY22's 6%

  • ROE 19.4%
  • ROIC (annual) 36%
  • Cost of capital 6.7%
FY25: ROE 19%, the climb back from FY22's 6%
QuarterROEROIC (annual)Cost of capital
FY225.9%6.8%6.7%
FY2327.4%55.3%6.7%
FY2423.9%74.4%6.7%
FY2519.4%36%6.7%
Return on equity each year, % (line); ROIC each year, % (line). 4-year window, low years included. The flat line is the 6.7% cost of capital used on this page.

Jun 2026: ROIC 24.6% (last 12 months) against a 6.7% cost of capital

  • ROIC (12 months) 24.6%
  • ROE (12 months) 17%
  • Cost of capital 6.7%
Jun 2026: ROIC 24.6% (last 12 months) against a 6.7% cost of capital
QuarterROIC (12 months)ROE (12 months)Cost of capital
Dec 2022–0%6.7%
Jun 2023––6.7%
Mar 202431%–6.7%
Jun 202453.6%50.9%6.7%
Sep 202475.3%47.6%6.7%
Dec 202470.4%6.2%6.7%
Mar 202569.7%13.1%6.7%
Jun 202564.5%40.8%6.7%
Sep 202545.2%4.1%6.7%
Dec 202550.5%20.8%6.7%
Mar 202635%22.3%6.7%
Jun 202624.6%17%6.7%
ROIC and ROE over the last 12 months, each quarter, %; the flat line is the cost of capital. Last 12 quarters, lined up with the yearly figure.

Does SBC Medical Group Holdings have too much debt?

SBC Medical Group Holdings Incorporated has total debt of $48.2 M against shareholder equity of $280 M as of Jun 2026, so its debt is 0.17× its equity, which is very little. Year by year, that ratio went from 0.15 in FY22 to 0.20 in FY25. So the returns on this page come from the business, not from borrowed money.

Debt-to-equity shows how much of the business is paid for with borrowed money. Lower is safer, and the direction matters as much as the level.

FY25: debt $51.6 M, 0.20× equity

  • Total debt $51.6 M
FY25: debt $51.6 M, 0.20× equity
QuarterTotal debt
FY22$16.1 M
FY23$22.9 M
FY24$12.2 M
FY25$51.6 M

Debt-to-equity

  • Debt-to-equity 0.20×
Debt-to-equity
QuarterDebt-to-equity
FY220.15×
FY230.16×
FY240.06×
FY250.20×
Top: total debt each year, $ M. Below: debt-to-equity, ×. 4-year window.

Jun 2026: debt $48.2 M, debt-to-equity 0.17

  • Total debt (quarterly) $48.2 M
Jun 2026: debt $48.2 M, debt-to-equity 0.17
QuarterTotal debt (quarterly)
Mar 2023$16.1 M
Dec 2023$22.9 M
Mar 2024$30.6 M
Jun 2024$29.5 M
Sep 2024$28.3 M
Dec 2024$12.2 M
Mar 2025$14.1 M
Jun 2025$15.5 M
Sep 2025$28.2 M
Dec 2025$51.6 M
Mar 2026$51.9 M
Jun 2026$48.2 M

Debt-to-equity

  • Debt-to-equity 0.17×
Debt-to-equity
QuarterDebt-to-equity
Mar 20230.15×
Dec 20230.16×
Mar 20240.20×
Jun 20240.18×
Sep 20240.14×
Dec 20240.06×
Mar 20250.06×
Jun 20250.06×
Sep 20250.11×
Dec 20250.20×
Mar 20260.19×
Jun 20260.17×
Top: total debt each quarter, $ M. Below: debt-to-equity, ×. Last 12 quarters.

What is the SBC Medical Group Holdings shareholding pattern?

4.2% of SBC Medical Group Holdings Incorporated's tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.5 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead.

There is no quarter-by-quarter list of owners here, so we look at short interest: the share of tradable shares held in short positions, which gain if the price falls.

It is a single reading at one point in time; we do not have its history.

4.2%Short interest · of the tradable float
3.5Days to cover · at typical volumes

Why it is at this level: the figure does not say who has the short positions or why, so we show the level without guessing the story.

How far is SBC Medical Group Holdings from balance-sheet trouble?

For SBC Medical Group Holdings Incorporated, the Z-score is 4.33. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure.

The Z-score estimates how far a company is from balance-sheet trouble. Above about 3 is safe; below about 1.8 is the danger zone. It was built for manufacturers, so it is not used for banks and lenders.

Why it matters: a Z-score of 4.33 is well clear of the danger zone, so the balance sheet is not the risk here.

How does SBC Medical Group Holdings rank in its industry?

73.7 out of 100, rank 1 of 13 in Consulting Services, with 81% of the evidence available.

SBC Medical Group Holdings Incorporated scores 73.7 out of 100 against the 13 companies it is compared with in Consulting Services, ranking 1. The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.

The four parts add up to the total exactly: 20.1 + 17.4 + 16.2 + 20 = 73.7. This is the same number shown on the industry page; it is worked out once for the whole group and read here.

What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector.

Which companies is SBC Medical Group Holdings compared with?

SBC Medical Group Holdings ranks 1 of 13 Consulting Services companies on the 4-Factor Sector Score, with 73.7 out of 100.

  1. 1SBC Medical Group Holdings Incorporated this pageSBC · leader · Most evidence points up · 81% evidence73.7out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.1/35 · Revenue -6.4% · Profit 44.1% · Operating margin change 4.9 points · 83% evidenceCapital efficiency 17.4/25 · ROCE 19.9% · Operating margin 38.5% · 76% evidenceValuation 16.2/20 · P/E 6.4× · PEG 0.14 · 65% evidenceRelative strength 20.0/20 · Lead over its industry 11.4% · Lead over S&P 500 26% · 1 year 68.9% · 100% evidence · 12 of 12 weeks aheadExact sum: 20.1 + 17.4 + 16.2 + 20 = 73.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  2. 2Huron Consulting Group Inc.HURN · breaking out · Most evidence points up · 81% evidence65.9out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 24.3/35 · Revenue 13.9% · Profit 9.5% · Operating margin change 0.2 points · 83% evidenceCapital efficiency 15.3/25 · ROCE 16.1% · Operating margin 11.7% · 76% evidenceValuation 14.2/20 · P/E 11.9× · PEG 0.71 · 65% evidenceRelative strength 12.1/20 · Lead over its industry -1.5% · Lead over S&P 500 11.4% · 1 year 4.4% · 100% evidence · 12 of 12 weeks aheadExact sum: 24.3 + 15.3 + 14.2 + 12.1 = 65.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  3. 3FTI Consulting, Inc.FCN · turning · Evidence leans up · 81% evidence59.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 17.3/35 · Revenue 7.1% · Profit 1.6% · Operating margin change -1.3 points · 83% evidenceCapital efficiency 13.4/25 · ROCE 14% · Operating margin 9.2% · 76% evidenceValuation 11.8/20 · P/E 17.4× · PEG 1.06 · 65% evidenceRelative strength 16.8/20 · Lead over its industry -0.1% · Lead over S&P 500 13.6% · 1 year 21.4% · 100% evidence · 2 of 12 weeks aheadExact sum: 17.3 + 13.4 + 11.8 + 16.8 = 59.3 · What this means: Relative strength against the index is 13.6%, and revenue and profit growth are weak.
  4. 4Equifax Inc.EFX · turning · Evidence leans up · 85% evidence54.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 25.8/35 · Revenue 10.9% · Profit 13.1% · Operating margin change 3.9 points · 95% evidenceCapital efficiency 13.7/25 · ROCE 11.6% · Operating margin 21% · 76% evidenceValuation 9.5/20 · P/E 21.7× · PEG 1.27 · 65% evidenceRelative strength 5.6/20 · Lead over its industry -14.7% · Lead over S&P 500 -2.9% · 1 year -7.4% · 100% evidence · 4 of 12 weeks aheadExact sum: 25.8 + 13.7 + 9.5 + 5.6 = 54.6 · What this means: Earnings are strong; relative strength in its sector is -14.7% and the one-year return is -7.4%.
  5. 5Verisk Analytics, Inc.VRSK · turning · Too little evidence to rank firmly · 56% evidence53.6out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.1/35 · Revenue — · Profit — · Operating margin change -0.8 points · 39% evidenceCapital efficiency 20.8/25 · ROCE 41.7% · Operating margin 45.1% · 76% evidenceValuation 8.5/20 · P/E 26.6× · PEG — · 15% evidenceRelative strength 3.2/20 · Lead over its industry -15.8% · Lead over S&P 500 -4.3% · 1 year -7.8% · 100% evidence · 2 of 12 weeks aheadExact sum: 21.1 + 20.8 + 8.5 + 3.2 = 53.6 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  6. 6CRA International, Inc.CRAI · breaking out · Evidence leans up · 85% evidence53.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 20.3/35 · Revenue 8.8% · Profit -12.5% · Operating margin change 1.9 points · 95% evidenceCapital efficiency 18.5/25 · ROCE 30.2% · Operating margin 11.2% · 76% evidenceValuation 4.2/20 · P/E 19.3× · PEG 3.24 · 65% evidenceRelative strength 10.1/20 · Lead over its industry -6.4% · Lead over S&P 500 6.1% · 1 year 8% · 100% evidence · 10 of 12 weeks aheadExact sum: 20.3 + 18.5 + 4.2 + 10.1 = 53.1 · What this means: A strong business with a high valuation: it would need rising earnings, or a lower multiple, to score better on value.
  7. 7Booz Allen Hamilton Holding CorporationBAH · breaking out · Evidence leans down · 85% evidence49.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 10.9/35 · Revenue -6.2% · Profit -5.4% · Operating margin change -1 points · 95% evidenceCapital efficiency 14.2/25 · ROCE 16.6% · Operating margin 8.8% · 76% evidenceValuation 15.2/20 · P/E 10.7× · PEG 0.24 · 65% evidenceRelative strength 8.9/20 · Lead over its industry -8.3% · Lead over S&P 500 4.3% · 1 year 1% · 100% evidence · 7 of 12 weeks aheadExact sum: 10.9 + 14.2 + 15.2 + 8.9 = 49.2 · What this means: The valuation scores well, but earnings are not improving yet, so the business does not back up the low multiple so far.
  8. 8ICF International, Inc.ICFI · losing its lead · Evidence leans down · 81% evidence44.1out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 12.3/35 · Revenue -7.9% · Profit -18.4% · Operating margin change 0 points · 83% evidenceCapital efficiency 10.0/25 · ROCE 8.4% · Operating margin 8.4% · 76% evidenceValuation 9.7/20 · P/E 14.9× · PEG 1.42 · 65% evidenceRelative strength 12.1/20 · Lead over its industry -0.2% · Lead over S&P 500 13% · 1 year 18.5% · 100% evidence · 11 of 12 weeks aheadExact sum: 12.3 + 10 + 9.7 + 12.1 = 44.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  9. 9Forrester Research, Inc.FORR · losing its lead · Most evidence points down · 64% evidence34.3out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 11.1/35 · Revenue -8% · Profit — · Operating margin change -1.2 points · 62% evidenceCapital efficiency 5.8/25 · ROCE 1.8% · Operating margin 5.5% · 76% evidenceValuation 11.5/20 · P/E -3.8× · PEG — · 15% evidenceRelative strength 5.9/20 · Lead over its industry -5.9% · Lead over S&P 500 5.7% · 1 year 24.5% · 100% evidence · 10 of 12 weeks aheadExact sum: 11.1 + 5.8 + 11.5 + 5.9 = 34.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer.
  10. 10Zi Yun Dong Fang LimitedYLY · Too little evidence to rank firmly · 11% evidence57.2out of 100GrowthCapitalValuationRelative
    How the score adds upGrowth & earnings 21.9/43.75 · Revenue — · Profit — · Operating margin change — · 0% evidenceCapital efficiency 22.8/31.25 · ROCE 110.6% · Operating margin — · 46% evidenceValuation 12.5/25 · P/E — · PEG — · 0% evidenceRelative strength: no reading this week · its 20 points are shared across the other threeExact sum: 21.9 + 22.8 + 12.5 = 57.2 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose.
  11. 11Etoiles Capital Group Co., LtdEFTY · Too little evidence to rank firmly · 19% evidence39.9out of 100GrowthCapitalValuationRelative
  12. 12Enigmatig LimitedEGG · Too little evidence to rank firmly · 19% evidence38.1out of 100GrowthCapitalValuationRelative
  13. 13Resources Connection, Inc.RGP · Too little evidence to rank firmly · 47% evidence27.3out of 100GrowthCapitalValuationRelative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read.

The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section.

Related companies: Consulting Services, all 13 compared on one page.

Which companies are close to SBC Medical Group Holdings in size?

SBC Medical Group Holdings is the 8th largest of 11 Consulting Services companies on Sector Alpha by market value (scores of 4 November 2026). Just above it: Huron Consulting Group Inc., ICF International, Inc. and CRA International, Inc. Just below it: Roma Green Finance, Etoiles Capital Group Co. and Forrester Research, Inc.

Consulting Services companies close in size

  1. Huron Consulting Group Inc. $2.6 billion
  2. ICF International, Inc. $1.7 billion
  3. CRA International, Inc. $1.2 billion
  4. SBC Medical Group Holdings Incorporated $547 million
  5. Roma Green Finance Limited $387 million
  6. Etoiles Capital Group Co., Ltd $302 million
  7. Forrester Research, Inc. $178 million

All 11 Consulting Services companies, largest first

Companies close in size in other industries

  1. Sierra Bancorp $537 million · Banks - Regional
  2. Gaotu Techedu Inc. $536 million · Education & Training Services
  3. SBC Medical Group Holdings Incorporated $536 million
  4. Hyliion Holdings Corp. $536 million · Auto Parts
  5. Methode Electronics, Inc. $536 million · Electronic Components

What else do people ask about SBC Medical Group Holdings?

What were SBC Medical Group Holdings's latest quarterly results?

SBC Medical Group Holdings Incorporated reported revenue of $49.2 M and net profit of $10.7 M for the Jun 2026 quarter. Revenue rose 13.4% and profit rose 335.0% compared with a year earlier. Earnings per share were $0.10 (as of 4 November 2026).

What is SBC Medical Group Holdings's market cap?

SBC Medical Group Holdings Incorporated's market capitalisation is $547 M at a stock price of $5.32. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026).

How is SBC Medical Group Holdings performing?

SBC Medical Group Holdings Incorporated's latest readings are below. In its latest quarter, revenue rose 13.4% and profit rose 335.0% compared with a year earlier. Over the past 13 weeks it has done better than the S&P 500, for 13 weeks running (as of 4 November 2026).

Will SBC Medical Group Holdings's stock price go up?

This page does not forecast SBC Medical Group Holdings Incorporated's stock price. What it shows instead: the stock price is $5.32. Its P/E of 11.1× is higher than 79% of its own last 1 years (as of 4 November 2026).

Where is SBC Medical Group Holdings in its business cycle?

SBC Medical Group Holdings Incorporated's FY25 operating margin was 38.9%, against a 4-year range of 11.7% to 41.6%: the middle of its own range, neither a peak nor a low. The latest quarter was 38.5%.

Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026).

What could break the SBC Medical Group Holdings story?

The main question: the share price moved +68.9% in a year while yearly earnings per share moved +2.5%. The difference came from the market paying a higher multiple.

On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026).

Is SBC Medical Group Holdings a stock worth studying right now?

What the numbers show: SBC Medical Group Holdings Incorporated's share price has risen faster than its earnings: +68.9% in a year, against +2.5% for earnings per share. The main open question: whether earnings grow into a price that has already moved.

Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026).

Where do these numbers come from?

Sector Alpha, written by code from the published numbers. Data as of 4 November 2026.

Every chart on this page is drawn by code from the published figures, with no forecasts and no price opinions.

See the plain-text version of this page.

More lists

Every Sector Alpha list, grouped

X · Instagram · YouTube · About · Newsletter · Newsletter archive
This is research, not advice. We’re not SEBI-registered.